EnigmaSoft's SpyHunter Scores 100% with AV-TEST in 2024
Thursday, April 25, 2024
EnigmaSoft Limited's SpyHunter earned top marks in rigorous AV-TEST evaluation, achieving a perfect 100% anti-malware protection score and solidifying its reputation as a robust malware defense solution.
DUBLIN, April 17, 2024 /PRNewswire/ -- EnigmaSoft is proud to announce that its premier anti-malware protection and remediation application, SpyHunter scored 100% in AV-TEST's rigorous Protection category, demonstrating exceptional performance in AV-TEST's independent, comprehensive testing program. SpyHunter also met and exceeded AV-TEST's criteria for the Performance and Usability test categories.
AV-TEST is a German-based leading international IT security and anti-virus testing lab. AV-TEST rigorously evaluated SpyHunter's anti-malware protection capabilities. The test confirmed SpyHunter's ability to block, detect, and eliminate active malware components across various samples and scenarios. SpyHunter protected against and blocked 100% of the malware samples while defending a test computer against malicious URLs and prevalent/zero-day malware files.
The AV-TEST 2024 Report of SpyHunter's test results is available at AV-TEST SpyHunter Test Report. The report is also available in German, French, and Spanish.
To learn more about SpyHunter and get your FREE Trial, go to
https://www.enigmasoftware.com/products/spyhunter/.
Patrick Morganelli, CEO of EnigmaSoft Limited, said of the news, "These recent exceptional test scores demonstrate and confirm the high quality and effectiveness of SpyHunter, which also received exceptionally high test scores in previous AV-TEST independent testing."
SpyHunter Enhances Security and Privacy Protection
SpyHunter offers a multitude of premium features, including:
-- Malware & PUP Detection & Removal
-- Advanced Guards to Block Malware
-- Optimization Scan & Functionality
-- Vulnerability Detection
-- File Shredder
-- Secure Disk Erase
-- Duplicate File Scan
-- Large File Scan
-- Enhanced Privacy Protection
-- One-on-One Customer Support
To learn more about SpyHunter and other EnigmaSoft security products, please visit https://www.enigmasoftware.com/products/.
About EnigmaSoft Limited
EnigmaSoft Limited is a privately held Irish company with offices and global headquarters in Dublin, Ireland. EnigmaSoft is best known for developing and distributing SpyHunter and SpyHunter for Mac, advanced anti-malware apps. SpyHunter detects and removes malware, enhances Internet privacy, and eliminates security threats - addressing issues such as malware, ransomware, trojans, rogue anti-spyware, and other malicious security threats affecting millions of computer users on the web. SpyHunter has scored top grades in comparative testing by independent third-party testing labs such as AV-TEST. SpyHunter has also been certified by AppEsteem and Checkmark Certified.
Connect with EnigmaSoft: Twitter | Facebook | LinkedIn | YouTube
View original content to download multimedia:https://www.prnewswire.com/news-releases/enigmasofts-spyhunter-scores-100-with-av-test-in-2024-302118828.html
SOURCE EnigmaSoft Limited
|
|
|
|
|
 |
Identiv Completes Thailand Manufacturing Transition, Unlocking Next-Generation Multicomponent Manufacturing for Advanced IoT Solutions | Jan 22, 2026
|
|
Global Cyber Alliance Identifies Five Cybersecurity Forces That Defined 2025 - And Will Shape 2026 | Jan 22, 2026
|
|
LG ELECTRONICS INTRODUCES 2026 LG GRAM LINEUP ELEVATED BY AEROMINUM | Jan 22, 2026
|
|
New Report Names States Most Vulnerable to Holiday Scams | Jan 22, 2026
|
|
pgEdge Announces pgEdge Agentic AI Toolkit for Postgres | Jan 22, 2026
|
|
Truvista Fiber Acquires SlyTel | Jan 22, 2026
|
|
Android Mobile Adware Surges in Second Half of 2025 | Jan 22, 2026
|
|
Guardz 2025 SMB Cybersecurity Report: Nearly 50% of U.S. Small Businesses Have Been Hit by Cyber Attack | Jan 22, 2026
|
|
Healthcare Industry Executives are Likely to be Personal Targets of Cybercrime | Jan 22, 2026
|
|
Breakthrough Progress: METiS TechBio Publishes Consecutive Research Findings in Nature Communications and the Journal for ImmunoTherapy of Cancer | Jan 22, 2026
|
|
|
